

**Table S1.** Search strategy and results in this study.

Search strings	Modifiers	Date of search	Results
<b>COVID-19</b>			
Title: recommendation CONTAINS Subject: COVID-19	All of IRIS	18.05.2024.	108
Title: guide CONTAINS Subject: COVID-19	All of IRIS	18.05.2024.	35
Title: guideline CONTAINS Subject: COVID-19	All of IRIS	18.05.2024.	34
Title: guidance CONTAINS Subject: COVID-19	All of IRIS	18.05.2024.	286
Title: policy CONTAINS Subject: COVID-19	All of IRIS	18.05.2024.	74
Title: plan CONTAINS Subject: COVID-19	All of IRIS	18.05.2024.	53
Title: strategy CONTAINS Subject: COVID-19	All of IRIS	18.05.2024.	36
Title: recommendation CONTAINS Title: COVID-19	All of IRIS	18.05.2024.	101
Title: guide CONTAINS Title: COVID-19	All of IRIS	18.05.2024.	27
Title: guideline CONTAINS Title: COVID-19	All of IRIS	18.05.2024.	33
Title: guidance CONTAINS Title: COVID-19	All of IRIS	18.05.2024.	253
Title: policy CONTAINS Title: COVID-19	All of IRIS	18.05.2024.	73
Title: plan CONTAINS Title: COVID-19	All of IRIS	18.05.2024.	48
Title: strategy CONTAINS Title: COVID-19	All of IRIS	18.05.2024.	28
Subject: recommendation CONTAINS Title: COVID-19	All of IRIS	18.05.2024.	0
Subject: guide CONTAINS Title: COVID-19	All of IRIS	18.05.2024.	2
Subject: guideline CONTAINS Title: COVID-19	All of IRIS	18.05.2024.	602
Subject: guidance CONTAINS Title: COVID-19	All of IRIS	18.05.2024.	0
Subject: policy CONTAINS Title: COVID-19	All of IRIS	18.05.2024.	112
Subject: plan CONTAINS Title: COVID-19	All of IRIS	18.05.2024.	105
Subject: strategy CONTAINS Title: COVID-19	All of IRIS	18.05.2024.	0
Subject: recommendation CONTAINS Subject: COVID-19	All of IRIS	18.05.2024.	0
Subject: guide CONTAINS Subject: COVID-19	All of IRIS	18.05.2024.	2
Subject: guideline CONTAINS Subject: COVID-19	All of IRIS	18.05.2024.	673
Subject: guidance CONTAINS Subject: COVID-19	All of IRIS	18.05.2024.	0
Subject: policy CONTAINS Subject: COVID-19	All of IRIS	18.05.2024.	147
Subject: plan CONTAINS Subject: COVID-19	All of IRIS	18.05.2024.	246
Subject: strategy CONTAINS Subject: COVID-19	All of IRIS	18.05.2024.	1
Title: recommendation CONTAINS Subject: SARS-CoV-2	All of IRIS	24.05.2024.	2
Title: guide CONTAINS Subject: SARS-CoV-2	All of IRIS	24.05.2024.	2
Title: guideline CONTAINS Subject: SARS-CoV-2	All of IRIS	24.05.2024.	0
Title: guidance CONTAINS Subject: SARS-CoV-2	All of IRIS	24.05.2024.	5
Title: policy CONTAINS Subject: SARS-CoV-2	All of IRIS	24.05.2024.	4
Title: plan CONTAINS Subject: SARS-CoV-2	All of IRIS	24.05.2024.	6
Title: strategy CONTAINS Subject: SARS-CoV-2	All of IRIS	24.05.2024.	0
Title: recommendation CONTAINS Title: SARS-CoV-2	All of IRIS	24.05.2024.	1
Title: guide CONTAINS Title: SARS-CoV-2	All of IRIS	24.05.2024.	5
Title: guideline CONTAINS Title: SARS-CoV-2	All of IRIS	24.05.2024.	1
Title: guidance CONTAINS Title: SARS-CoV-2	All of IRIS	24.05.2024.	23
Title: policy CONTAINS Title: SARS-CoV-2	All of IRIS	24.05.2024.	0
Title: plan CONTAINS Title: SARS-CoV-2	All of IRIS	24.05.2024.	0
Title: strategy CONTAINS Title: SARS-CoV-2	All of IRIS	24.05.2024.	3
Subject: recommendation CONTAINS Title: SARS-CoV-2	All of IRIS	24.05.2024.	0
Subject: guide CONTAINS Title: SARS-CoV-2	All of IRIS	24.05.2024.	0
Subject: guideline CONTAINS Title: SARS-CoV-2	All of IRIS	24.05.2024.	66
Subject: guidance CONTAINS Title: SARS-CoV-2	All of IRIS	24.05.2024.	0

Subject: policy CONTAINS Title: SARS-CoV-2	All of IRIS	24.05.2024.	6
Subject: plan CONTAINS Title: SARS-CoV-2	All of IRIS	24.05.2024.	0
Subject: strategy CONTAINS Title: SARS-CoV-2	All of IRIS	24.05.2024.	0
Subject: recommendation CONTAINS Subject: SARS-	All of IRIS	24.05.2024.	0
Subject: guide CONTAINS Subject: SARS-CoV-2	All of IRIS	24.05.2024.	0
Subject: guideline CONTAINS Subject: SARS-CoV-2	All of IRIS	24.05.2024.	14
Subject: guidance CONTAINS Subject: SARS-CoV-2	All of IRIS	24.05.2024.	0
Subject: policy CONTAINS Subject: SARS-CoV-2	All of IRIS	24.05.2024.	8
Subject: plan CONTAINS Subject: SARS-CoV-2	All of IRIS	24.05.2024.	5
Subject: strategy CONTAINS Subject: SARS-CoV-2	All of IRIS	24.05.2024.	0
<b>Total</b>			<b>3230</b>

## SARS

Title: recommendation CONTAINS Subject: SARS-CoV	All of IRIS	18.05.2024.	2
Title: guide CONTAINS Subject: SARS-CoV	All of IRIS	18.05.2024.	2
Title: guideline CONTAINS Subject: SARS-CoV	All of IRIS	18.05.2024.	0
Title: guidance CONTAINS Subject: SARS-CoV	All of IRIS	18.05.2024.	5
Title: policy CONTAINS Subject: SARS-CoV	All of IRIS	18.05.2024.	4
Title: plan CONTAINS Subject: SARS-CoV	All of IRIS	18.05.2024.	6
Title: strategy CONTAINS Subject: SARS-CoV	All of IRIS	18.05.2024.	0
Title: recommendation CONTAINS Title: SARS	All of IRIS	18.05.2024.	3
Title: guide CONTAINS Title: SARS-CoV	All of IRIS	18.05.2024.	5
Title: guideline CONTAINS Title: SARS	All of IRIS	18.05.2024.	2
Title: guidance CONTAINS Title: SARS-CoV	All of IRIS	18.05.2024.	23
Title: policy CONTAINS Title: SARS-CoV	All of IRIS	18.05.2024.	0
Title: plan CONTAINS Title: SARS-CoV	All of IRIS	18.05.2024.	0
Title: strategy CONTAINS Title: SARS-CoV	All of IRIS	18.05.2024.	3
Subject: recommendation CONTAINS Title: SARS-CoV	All of IRIS	18.05.2024.	0
Subject: guide CONTAINS Title: SARS-CoV	All of IRIS	18.05.2024.	0
Subject: guideline CONTAINS Title: SARS-CoV	All of IRIS	18.05.2024.	66
Subject: guidance CONTAINS Title: SARS-CoV	All of IRIS	18.05.2024.	0
Subject: policy CONTAINS Title: SARS-CoV	All of IRIS	18.05.2024.	6
Subject: plan CONTAINS Title: SARS-CoV	All of IRIS	18.05.2024.	0
Subject: strategy CONTAINS Title: SARS-CoV	All of IRIS	18.05.2024.	0
Subject: recommendation CONTAINS Subject: SARS-CoV	All of IRIS	18.05.2024.	0
Subject: guide CONTAINS Subject: SARS-CoV	All of IRIS	18.05.2024.	0
Subject: guideline CONTAINS Subject: SARS-CoV	All of IRIS	18.05.2024.	14
Subject: guidance CONTAINS Subject: SARS-CoV	All of IRIS	18.05.2024.	0
Subject: policy CONTAINS Subject: SARS-CoV	All of IRIS	18.05.2024.	8
Subject: plan CONTAINS Subject: SARS-CoV	All of IRIS	18.05.2024.	5
Subject: strategy CONTAINS Subject: SARS-CoV	All of IRIS	18.05.2024.	0
Date issued: 2000-2018 CONTAINS Title: SARS	All of IRIS	18.05.2024.	27
<b>Total</b>			<b>181</b>

## H1N1

Title: recommendation CONTAINS Subject: H1N1	All of IRIS	19.05.2024.	1
Title: guide CONTAINS Subject: H1N1	All of IRIS	19.05.2024.	0
Title: guideline CONTAINS Subject: H1N1	All of IRIS	19.05.2024.	1
Title: guidance CONTAINS Subject: H1N1	All of IRIS	19.05.2024.	0
Title: policy CONTAINS Subject: H1N1	All of IRIS	19.05.2024.	0
Title: plan CONTAINS Subject: H1N1	All of IRIS	19.05.2024.	3
Title: strategy CONTAINS Subject: H1N1	All of IRIS	19.05.2024.	2

Title: recommendation CONTAINS Title: H1N1	All of IRIS	19.05.2024.	0
Title: guide CONTAINS Title: H1N1	All of IRIS	19.05.2024.	0
Title: guideline CONTAINS Title: H1N1	All of IRIS	19.05.2024.	0
Title: guidance CONTAINS Title: H1N1	All of IRIS	19.05.2024.	0
Title: policy CONTAINS Title: H1N1	All of IRIS	19.05.2024.	0
Title: plan CONTAINS Title: H1N1	All of IRIS	19.05.2024.	0
Title: strategy CONTAINS Title: H1N1	All of IRIS	19.05.2024.	3
Subject: recommendation CONTAINS Title: H1N1	All of IRIS	19.05.2024.	0
Subject: guide CONTAINS Title: H1N1	All of IRIS	19.05.2024.	0
Subject: guideline CONTAINS Title: H1N1	All of IRIS	19.05.2024.	0
Subject: guidance CONTAINS Title: H1N1	All of IRIS	19.05.2024.	0
Subject: policy CONTAINS Title: H1N1	All of IRIS	19.05.2024.	0
Subject: plan CONTAINS Title: H1N1	All of IRIS	19.05.2024.	0
Subject: strategy CONTAINS Title: H1N1	All of IRIS	19.05.2024.	0
Subject: recommendation CONTAINS Subject: H1N1	All of IRIS	19.05.2024.	0
Subject: guide CONTAINS Subject: H1N1	All of IRIS	19.05.2024.	0
Subject: guideline CONTAINS Subject: H1N1	All of IRIS	19.05.2024.	10
Subject: guidance CONTAINS Subject: H1N1	All of IRIS	19.05.2024.	0
Subject: policy CONTAINS Subject: H1N1	All of IRIS	19.05.2024.	6
Subject: plan CONTAINS Subject: H1N1	All of IRIS	19.05.2024.	29
Subject: strategy CONTAINS Subject: H1N1	All of IRIS	19.05.2024.	0
Title: recommendation CONTAINS Subject: Influenza A Virus	All of IRIS	19.05.2024.	3
Title: guide CONTAINS Subject: Influenza A Virus	All of IRIS	19.05.2024.	2
Title: guideline CONTAINS Subject: Influenza A Virus	All of IRIS	19.05.2024.	4
Title: guidance CONTAINS Subject: Influenza A Virus	All of IRIS	19.05.2024.	1
Title: policy CONTAINS Subject: Influenza A Virus	All of IRIS	19.05.2024.	2
Title: plan CONTAINS Subject: Influenza A Virus	All of IRIS	19.05.2024.	7
Title: strategy CONTAINS Subject: Influenza A Virus	All of IRIS	19.05.2024.	9
Title: recommendation CONTAINS Title: Influenza A Virus	All of IRIS	19.05.2024.	79
Title: guide CONTAINS Title: Influenza A Virus	All of IRIS	19.05.2024.	1
Title: guideline CONTAINS Title: Influenza A Virus	All of IRIS	19.05.2024.	2
Title: guidance CONTAINS Title: Influenza A Virus	All of IRIS	19.05.2024.	5
Title: policy CONTAINS Title: Influenza A Virus	All of IRIS	19.05.2024.	0
Title: plan CONTAINS Title: Influenza A Virus	All of IRIS	19.05.2024.	1
Title: strategy CONTAINS Title: Influenza A Virus	All of IRIS	19.05.2024.	1
Subject: recommendation CONTAINS Title: Influenza A Virus	All of IRIS	19.05.2024.	0
Subject: guide CONTAINS Title: Influenza A Virus	All of IRIS	19.05.2024.	0
Subject: guideline CONTAINS Title: Influenza A Virus	All of IRIS	19.05.2024.	4
Subject: guidance CONTAINS Title: Influenza A Virus	All of IRIS	19.05.2024.	0
Subject: policy CONTAINS Title: Influenza A Virus	All of IRIS	19.05.2024.	0
Subject: plan CONTAINS Title: Influenza A Virus	All of IRIS	19.05.2024.	17
Subject: strategy CONTAINS Title: Influenza A Virus	All of IRIS	19.05.2024.	0
Subject: recommendation CONTAINS Subject: Influenza A Virus	All of IRIS	19.05.2024.	0
Subject: guide CONTAINS Subject: Influenza A Virus	All of IRIS	19.05.2024.	0
Subject: guideline CONTAINS Subject: Influenza A Virus	All of IRIS	19.05.2024.	17
Subject: guidance CONTAINS Subject: Influenza A Virus	All of IRIS	19.05.2024.	0
Subject: policy CONTAINS Subject: Influenza A Virus	All of IRIS	19.05.2024.	15

Subject: plan CONTAINS Subject: Influenza A Virus	All of IRIS	19.05.2024.	60
Subject: strategy CONTAINS Subject: Influenza A Virus	All of IRIS	19.05.2024.	0
<b>Total</b>			<b>285</b>
<b>H7N9</b>			
Subject: H7N9	All of IRIS	18.05.2024.	19
Subject: influenza a virus, h7n9 subtype	All of IRIS	18.05.2024.	19
Subject: H7N9 Virus	All of IRIS	18.05.2024.	19
Subject: H7N9 subtype	All of IRIS	18.05.2024.	19
Title: H7N9	All of IRIS	18.05.2024.	0
Title: influenza a virus, h7n9 subtype	All of IRIS	18.05.2024.	0
Title: H7N9 Virus	All of IRIS	18.05.2024.	0
Title: H7N9 subtype	All of IRIS	18.05.2024.	0
<b>Total</b>			<b>76</b>
<b>MERS</b>			
Title: recommendation CONTAINS Subject: MERS	All of IRIS	18.05.2024.	0
Title: guide CONTAINS Subject: MERS	All of IRIS	18.05.2024.	0
Title: guideline CONTAINS Subject: MERS	All of IRIS	18.05.2024.	0
Title: guidance CONTAINS Subject: MERS	All of IRIS	18.05.2024.	0
Title: policy CONTAINS Subject: MERS	All of IRIS	18.05.2024.	0
Title: plan CONTAINS Subject: MERS	All of IRIS	18.05.2024.	0
Title: strategy CONTAINS Subject: MERS	All of IRIS	18.05.2024.	0
Title: recommendation CONTAINS Title: MERS	All of IRIS	18.05.2024.	0
Title: guide CONTAINS Title: MERS	All of IRIS	18.05.2024.	1
Title: guideline CONTAINS Title: MERS	All of IRIS	18.05.2024.	1
Title: guidance CONTAINS Title: MERS	All of IRIS	18.05.2024.	8
Title: policy CONTAINS Title: MERS	All of IRIS	18.05.2024.	0
Title: plan CONTAINS Title: MERS	All of IRIS	18.05.2024.	0
Title: strategy CONTAINS Title: MERS	All of IRIS	18.05.2024.	0
Subject: recommendation CONTAINS Title: MERS	All of IRIS	18.05.2024.	0
Subject: guide CONTAINS Title: MERS	All of IRIS	18.05.2024.	0
Subject: guideline CONTAINS Title: MERS	All of IRIS	18.05.2024.	0
Subject: guidance CONTAINS Title: MERS	All of IRIS	18.05.2024.	0
Subject: policy CONTAINS Title: MERS	All of IRIS	18.05.2024.	1
Subject: plan CONTAINS Title: MERS	All of IRIS	18.05.2024.	15
Subject: strategy CONTAINS Title: MERS	All of IRIS	18.05.2024.	0
Subject: recommendation CONTAINS Subject: MERS	All of IRIS	18.05.2024.	0
Subject: guide CONTAINS Subject: MERS	All of IRIS	18.05.2024.	0
Subject: guideline CONTAINS Subject: MERS	All of IRIS	18.05.2024.	0
Subject: guidance CONTAINS Subject: MERS	All of IRIS	18.05.2024.	0
Subject: policy CONTAINS Subject: MERS	All of IRIS	18.05.2024.	0
Subject: plan CONTAINS Subject: MERS	All of IRIS	18.05.2024.	0
Subject: strategy CONTAINS Subject: MERS	All of IRIS	18.05.2024.	0
Title: recommendation CONTAINS Subject: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0

Title: guide CONTAINS Subject: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	1
Title: guideline CONTAINS Subject: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Title: guidance CONTAINS Subject: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	10
Title: policy CONTAINS Subject: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Title: plan CONTAINS Subject: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Title: strategy CONTAINS Subject: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Title: recommendation CONTAINS Title: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Title: guide CONTAINS Title: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Title: guideline CONTAINS Title: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Title: guidance CONTAINS Title: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	10
Title: policy CONTAINS Title: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Title: plan CONTAINS Title: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Title: strategy CONTAINS Title: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Subject: recommendation CONTAINS Title: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Subject: guide CONTAINS Title: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Subject: guideline CONTAINS Title: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Subject: guidance CONTAINS Title: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Subject: policy CONTAINS Title: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Subject: plan CONTAINS Title: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Subject: strategy CONTAINS Title: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Subject: recommendation CONTAINS Subject: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Subject: guide CONTAINS Subject: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Subject: guideline CONTAINS Subject: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Subject: guidance CONTAINS Subject: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Subject: policy CONTAINS Subject: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0

Subject: plan CONTAINS Subject: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Subject: strategy CONTAINS Subject: Middle East Respiratory Syndrome Coronavirus	All of IRIS	18.05.2024.	0
Title: recommendation CONTAINS Subject: MERS-CoV	All of IRIS	18.05.2024.	0
Title: guide CONTAINS Subject: MERS-CoV	All of IRIS	18.05.2024.	0
Title: guideline CONTAINS Subject: MERS-CoV	All of IRIS	18.05.2024.	0
Title: guidance CONTAINS Subject: MERS-CoV	All of IRIS	18.05.2024.	0
Title: policy CONTAINS Subject: MERS-CoV	All of IRIS	18.05.2024.	0
Title: plan CONTAINS Subject: MERS-CoV	All of IRIS	18.05.2024.	0
Title: strategy CONTAINS Subject: MERS-CoV	All of IRIS	18.05.2024.	0
Title: recommendation CONTAINS Title: MERS-CoV	All of IRIS	18.05.2024.	0
Title: guide CONTAINS Title: MERS-CoV	All of IRIS	18.05.2024.	0
Title: guideline CONTAINS Title: MERS-CoV	All of IRIS	18.05.2024.	0
Title: guidance CONTAINS Title: MERS-CoV	All of IRIS	18.05.2024.	8
Title: policy CONTAINS Title: MERS-CoV	All of IRIS	18.05.2024.	0
Title: plan CONTAINS Title: MERS-CoV	All of IRIS	18.05.2024.	0
Title: strategy CONTAINS Title: MERS-CoV	All of IRIS	18.05.2024.	0
Subject: recommendation CONTAINS Title: MERS-CoV	All of IRIS	18.05.2024.	0
Subject: guide CONTAINS Title: MERS-CoV	All of IRIS	18.05.2024.	0
Subject: guideline CONTAINS Title: MERS-CoV	All of IRIS	18.05.2024.	0
Subject: guidance CONTAINS Title: MERS-CoV	All of IRIS	18.05.2024.	0
Subject: policy CONTAINS Title: MERS-CoV	All of IRIS	18.05.2024.	0
Subject: plan CONTAINS Title: MERS-CoV	All of IRIS	18.05.2024.	0
Subject: strategy CONTAINS Title: MERS-CoV	All of IRIS	18.05.2024.	0
Subject: recommendation CONTAINS Subject: MERS-CoV	All of IRIS	18.05.2024.	0
Subject: guide CONTAINS Subject: MERS-CoV	All of IRIS	18.05.2024.	0
Subject: guideline CONTAINS Subject: MERS-CoV	All of IRIS	18.05.2024.	0
Subject: guidance CONTAINS Subject: MERS-CoV	All of IRIS	18.05.2024.	0
Subject: policy CONTAINS Subject: MERS-CoV	All of IRIS	18.05.2024.	0
Subject: plan CONTAINS Subject: MERS-CoV	All of IRIS	18.05.2024.	0
Subject: strategy CONTAINS Subject: MERS-CoV	All of IRIS	18.05.2024.	0
<b>Total</b>			<b>55</b>
<b>EVD</b>			
Title: recommendation AND Subject: Ebola Hemorrhagic	All of IRIS	22.05.2024.	6
Title: guide AND Subject: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	7
Title: guideline AND Subject: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	12
Title: guidance AND Subject: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	23
Title: policy AND Subject: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	0
Title: plan AND Subject: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	9
Title: strategy AND Subject: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	1
Title: recommendation AND Title: Ebola Hemorrhagic	All of IRIS	22.05.2024.	0

Title: guide AND Title: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	0
Title: guideline AND Title: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	0
Title: guidance AND Title: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	0
Title: policy AND Title: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	0
Title: plan AND Title: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	0
Title: strategy AND Title: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	0
Subject: recommendation AND Title: Ebola Hemorrhagic	All of IRIS	22.05.2024.	0
Subject: guide AND Title: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	0
Subject: guideline AND Title: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	0
Subject: guidance AND Title: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	0
Subject: policy AND Title: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	0
Subject: plan AND Title: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	0
Subject: strategy AND Title: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	0
Subject: recommendation AND Subject: Ebola Hemorrhagic	All of IRIS	22.05.2024.	0
Subject: guide AND Subject: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	0
Subject: guideline AND Subject: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	19
Subject: guidance AND Subject: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	0
Subject: policy AND Subject: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	8
Subject: plan AND Subject: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	23
Subject: strategy AND Subject: Ebola Hemorrhagic Fever	All of IRIS	22.05.2024.	0
Title: recommendation AND Subject: Ebola Infection	All of IRIS	20.05.2024.	1
Title: guide AND Subject: Ebola Infection	All of IRIS	20.05.2024.	3
Title: guideline AND Subject: Ebola Infection	All of IRIS	20.05.2024.	4
Title: guidance AND Subject: Ebola Infection	All of IRIS	20.05.2024.	4
Title: policy AND Subject: Ebola Infection	All of IRIS	20.05.2024.	0
Title: plan AND Subject: Ebola Infection	All of IRIS	20.05.2024.	1
Title: strategy AND Subject: Ebola Infection	All of IRIS	20.05.2024.	0
Title: recommendation AND Title: Ebola Infection	All of IRIS	20.05.2024.	0
Title: guide AND Title: Ebola Infection	All of IRIS	20.05.2024.	4
Title: guideline AND Title: Ebola Infection	All of IRIS	20.05.2024.	2
Title: guidance AND Title: Ebola Infection	All of IRIS	20.05.2024.	6
Title: policy AND Title: Ebola Infection	All of IRIS	20.05.2024.	0
Title: plan AND Title: Ebola Infection	All of IRIS	20.05.2024.	0
Title: strategy AND Title: Ebola Infection	All of IRIS	20.05.2024.	0
Subject: recommendation AND Title: Ebola Infection	All of IRIS	20.05.2024.	0
Subject: guide AND Title: Ebola Infection	All of IRIS	20.05.2024.	0
Subject: guideline AND Title: Ebola Infection	All of IRIS	20.05.2024.	0
Subject: guidance AND Title: Ebola Infection	All of IRIS	20.05.2024.	0
Subject: policy AND Title: Ebola Infection	All of IRIS	20.05.2024.	0
Subject: plan AND Title: Ebola Infection	All of IRIS	20.05.2024.	0
Subject: strategy AND Title: Ebola Infection	All of IRIS	20.05.2024.	0

Subject: recommendation AND Subject: Ebola Infection	All of IRIS	20.05.2024.	0
Subject: guide AND Subject: Ebola Infection	All of IRIS	20.05.2024.	0
Subject: guideline AND Subject: Ebola Infection	All of IRIS	20.05.2024.	5
Subject: guidance AND Subject: Ebola Infection	All of IRIS	20.05.2024.	0
Subject: policy AND Subject: Ebola Infection	All of IRIS	20.05.2024.	1
Subject: plan AND Subject: Ebola Infection	All of IRIS	20.05.2024.	0
Subject: strategy AND Subject: Ebola Infection	All of IRIS	20.05.2024.	0
Title: recommendation AND Subject: Ebola Virus Disease	All of IRIS	20.05.2024.	2
Title: guide AND Subject: Ebola Virus Disease	All of IRIS	20.05.2024.	1
Title: guideline AND Subject: Ebola Virus Disease	All of IRIS	20.05.2024.	5
Title: guidance AND Subject: Ebola Virus Disease	All of IRIS	20.05.2024.	0
Title: policy AND Subject: Ebola Virus Disease	All of IRIS	20.05.2024.	0
Title: plan AND Subject: Ebola Virus Disease	All of IRIS	20.05.2024.	0
Title: strategy AND Subject: Ebola Virus Disease	All of IRIS	20.05.2024.	0
Title: recommendation AND Title: Ebola Virus Disease	All of IRIS	20.05.2024.	3
Title: guide AND Title: Ebola Virus Disease	All of IRIS	20.05.2024.	0
Title: guideline AND Title: Ebola Virus Disease	All of IRIS	20.05.2024.	5
Title: guidance AND Title: Ebola Virus Disease	All of IRIS	20.05.2024.	5
Title: policy AND Title: Ebola Virus Disease	All of IRIS	20.05.2024.	0
Title: plan AND Title: Ebola Virus Disease	All of IRIS	20.05.2024.	1
Title: strategy AND Title: Ebola Virus Disease	All of IRIS	20.05.2024.	0
Subject: recommendation AND Title: Ebola Virus Disease	All of IRIS	20.05.2024.	0
Subject: guide AND Title: Ebola Virus Disease	All of IRIS	20.05.2024.	0
Subject: guideline AND Title: Ebola Virus Disease	All of IRIS	20.05.2024.	7
Subject: guidance AND Title: Ebola Virus Disease	All of IRIS	20.05.2024.	0
Subject: policy AND Title: Ebola Virus Disease	All of IRIS	20.05.2024.	0
Subject: plan AND Title: Ebola Virus Disease	All of IRIS	20.05.2024.	0
Subject: strategy AND Title: Ebola Virus Disease	All of IRIS	20.05.2024.	0
Subject: recommendation AND Subject: Ebola Virus	All of IRIS	20.05.2024.	0
Subject: guide AND Subject: Ebola Virus Disease	All of IRIS	20.05.2024.	0
Subject: guideline AND Subject: Ebola Virus Disease	All of IRIS	20.05.2024.	6
Subject: guidance AND Subject: Ebola Virus Disease	All of IRIS	20.05.2024.	0
Subject: policy AND Subject: Ebola Virus Disease	All of IRIS	20.05.2024.	5
Subject: plan AND Subject: Ebola Virus Disease	All of IRIS	20.05.2024.	0
Subject: strategy AND Subject: Ebola Virus Disease	All of IRIS	20.05.2024.	0
<b>Total</b>			<b>179</b>

**Table S2.** The scoring and calculating methods in the manuals and in this study.

	<b>AGREE II Manual</b>	<b>AGREE II New<sup>3</sup></b>	<b>AGREE-HS Manua</b>	<b>AGREE-HS New<sup>3</sup></b>
Scoring target	23 items; overall score	-	5 items	5 items and 35 criteria
Item <sup>1</sup> /Criterion score	Raw score	-	-	Raw score
Domain/Item <sup>2</sup> score	Transformed score	-	Raw score	-
Overall score	Raw score	Average of domain scores	Transformed score	Average of item scores

<sup>1</sup> Twenty-three items for the AGREE II, same dimension as the criteria of AGREE-HS.

<sup>2</sup> Five items for the AGREE-HS tool, same dimension as the domains of AGREE II.

<sup>3</sup> New scoring and calculation methods adopted in this study.

- No change to the scoring methods in the manuals.

\* Raw score equals the mean score of two assessors' evaluating scores (1-7 points) on item/criterion/overall.

\*\* Transformed score means a linear transformation of raw scores.

**Table S3.** Characteristics of guidelines included in this study.

NO.	Title	Link	Guide type
1	Advice on the use of masks in the community, during home care, and in health care settings in the context of COVID-19: interim guidance, 19 March 2020	<a href="https://iris.who.int/handle/10665/331493">https://iris.who.int/handle/10665/331493</a>	Integrated guideline
2	Annex to Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed: interim guidance, 1 October 2021	<a href="https://iris.who.int/handle/10665/345682">https://iris.who.int/handle/10665/345682</a>	Integrated guideline
3	Clinical management of COVID-19: living guideline, 18 August 2023	<a href="https://iris.who.int/handle/10665/372288">https://iris.who.int/handle/10665/372288</a>	Integrated guideline
4	Coronavirus disease 2019 (COVID-19) strategic preparedness and response plan: Accelerating readiness in the Eastern Mediterranean Region: February 2020	<a href="https://iris.who.int/handle/10665/331950">https://iris.who.int/handle/10665/331950</a>	Integrated guideline
5	COVID-19 strategic preparedness and response plan: operational planning guideline: 1 February 2021 to 31 January 2022	<a href="https://iris.who.int/handle/10665/340073">https://iris.who.int/handle/10665/340073</a>	Integrated guideline
6	COVID-19 strategic preparedness and response plan: sustaining an effective response to end the acute phase of the pandemic and transitioning to recovery in WHO's Eastern Mediterranean Region, 2022 edition.	<a href="https://iris.who.int/handle/10665/354369">https://iris.who.int/handle/10665/354369</a>	Integrated guideline
7	COVID19 strategy update ( as of 14 April 2020)	<a href="https://iris.who.int/handle/10665/332019">https://iris.who.int/handle/10665/332019</a>	Integrated guideline
8	COVID-19: operationalization of the global response strategy in the WHO European Region: September 2020	<a href="https://iris.who.int/handle/10665/334167">https://iris.who.int/handle/10665/334167</a>	Integrated guideline
9	Drugs to prevent COVID-19: living guideline, 24 March 2023	<a href="https://iris.who.int/handle/10665/366530">https://iris.who.int/handle/10665/366530</a>	Integrated guideline
10	From emergency response to long-term COVID-19 disease management: ending the COVID-19 emergency and transitioning from emergency phase to longer-term disease management: guidance on calibrating the response	<a href="https://iris.who.int/handle/10665/372712">https://iris.who.int/handle/10665/372712</a>	Integrated guideline
11	Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance, 12 August	<a href="https://iris.who.int/handle/10665/333782">https://iris.who.int/handle/10665/333782</a>	Integrated guideline
12	Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected: interim guidance, 10 January 2020	<a href="https://iris.who.int/handle/10665/330674">https://iris.who.int/handle/10665/330674</a>	Integrated guideline
13	Infection prevention and control guidance for long-term care facilities in the context of COVID-19: interim guidance, 8 January 2021	<a href="https://iris.who.int/handle/10665/338481">https://iris.who.int/handle/10665/338481</a>	Integrated guideline
14	Infection prevention and control in the context of COVID-19: a guideline, 21 December 2023	<a href="https://iris.who.int/handle/10665/375200">https://iris.who.int/handle/10665/375200</a>	Integrated guideline

15	Interim recommendations for the use of inactivated COVID-19 vaccines: interim guidance 31 August 2023	<a href="https://iris.who.int/handle/10665/372713">https://iris.who.int/handle/10665/372713</a>	Integrated guideline
16	Maintaining essential health services: operational guidance for the COVID-19 context: interim guidance, 1 June 2020	<a href="https://iris.who.int/handle/10665/332240">https://iris.who.int/handle/10665/332240</a>	Integrated guideline
17	Mask use in the context of COVID-19: interim guidance, 1 December 2020	<a href="https://iris.who.int/handle/10665/337199">https://iris.who.int/handle/10665/337199</a>	Integrated guideline
18	Operational considerations for case management of COVID-19 in health facility and community: interim guidance, 19 March 2020	<a href="https://iris.who.int/handle/10665/331492">https://iris.who.int/handle/10665/331492</a>	Integrated guideline
19	Preparedness and resilience for emerging threats: module 1: planning for respiratory pathogen pandemics	<a href="https://iris.who.int/handle/10665/376312">https://iris.who.int/handle/10665/376312</a>	Integrated guideline
20	Prevention, identification and management of health worker infection in the context of COVID-19: interim guidance, 30 October	<a href="https://iris.who.int/handle/10665/336265">https://iris.who.int/handle/10665/336265</a>	Integrated guideline
21	Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages: interim guidance, 6 April 2020	<a href="https://iris.who.int/handle/10665/331695">https://iris.who.int/handle/10665/331695</a>	Integrated guideline
22	Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities: interim guidance, 25 June 2021	<a href="https://iris.who.int/handle/10665/342002">https://iris.who.int/handle/10665/342002</a>	Integrated guideline
23	Strategy considerations for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory viruses in the WHO European Region during autumn and winter 2022/23: protecting the vulnerable with agility, efficiency, and trust	<a href="https://iris.who.int/handle/10665/360408">https://iris.who.int/handle/10665/360408</a>	Integrated guideline
24	Therapeutics and COVID-19: living guideline, 22 April 2022	<a href="https://iris.who.int/handle/10665/353403">https://iris.who.int/handle/10665/353403</a>	Integrated guideline
25	Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing: interim guidance, 9 March 2022	<a href="https://iris.who.int/handle/10665/352350">https://iris.who.int/handle/10665/352350</a>	Integrated guideline
26	WHO Regional Office for Europe recommendations on influenza vaccination for the 2021/2022 season during the ongoing COVID-19 pandemic	<a href="https://iris.who.int/handle/10665/347890">https://iris.who.int/handle/10665/347890</a>	Integrated guideline
27	Global Surveillance for Severe Acute Respiratory Syndrome (SARS): Objective = Surveillance mondiale du syndrome respiratoire aigu sévère (SRAS): Objectif	<a href="https://iris.who.int/handle/10665/232131">https://iris.who.int/handle/10665/232131</a>	Integrated guideline
28	Hospital preparedness checklist for pandemic influenza: focus on pandemic (H1N1) 2009	<a href="https://iris.who.int/handle/10665/107964">https://iris.who.int/handle/10665/107964</a>	Integrated guideline
29	Home care for patients with Middle East respiratory syndrome coronavirus ( MERS-CoV) infection presenting with mild symptoms and management of contacts:	<a href="https://iris.who.int/handle/10665/272948">https://iris.who.int/handle/10665/272948</a>	Integrated guideline

30	Management of asymptomatic persons who are RT-PCR positive for Middle East respiratory syndrome coronavirus ( MERS-CoV): interim guidance	<a href="https://iris.who.int/handle/10665/180973">https://iris.who.int/handle/10665/180973</a>	Integrated guideline
31	Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus ( MERS-CoV) infection is suspected: interim guidance	<a href="https://iris.who.int/handle/10665/178529">https://iris.who.int/handle/10665/178529</a>	Integrated guideline
32	Infection prevention and control during health care for probable or confirmed cases of Middle East respiratory syndrome coronavirus ( MERS-CoV) infection: interim guidance: updated October 2019	<a href="https://iris.who.int/handle/10665/174652">https://iris.who.int/handle/10665/174652</a>	Integrated guideline
33	Interim infection prevention and control guidance for care of patients with suspected or confirmed filovirus haemorrhagic fever in health-care settings, with focus on Ebola	<a href="https://iris.who.int/handle/10665/130596">https://iris.who.int/handle/10665/130596</a>	Integrated guideline
34	Infection prevention and control (IPC) guidance summary: Ebola guidance package	<a href="https://iris.who.int/handle/10665/131828">https://iris.who.int/handle/10665/131828</a>	Integrated guideline
35	Guidelines for the management of pregnant and breastfeeding women in the context of Ebola virus disease	<a href="https://iris.who.int/handle/10665/330851">https://iris.who.int/handle/10665/330851</a>	Integrated guideline
36	WHO recommended guidelines for epidemic preparedness and response: Ebola haemorrhagic fever (EHF)	<a href="https://iris.who.int/handle/10665/63806">https://iris.who.int/handle/10665/63806</a>	Integrated guideline
37	Therapeutics and COVID-19: living guideline, 10 November 2023	<a href="https://iris.who.int/handle/10665/373975">https://iris.who.int/handle/10665/373975</a>	Clinical practice guideline
38	Interim recommendations for the use of protein subunit COVID-19 vaccines: interim guidance 31 August 2023	<a href="https://iris.who.int/handle/10665/372724">https://iris.who.int/handle/10665/372724</a>	Clinical practice guideline
39	Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19)	<a href="https://iris.who.int/handle/10665/366678">https://iris.who.int/handle/10665/366678</a>	Clinical practice guideline
40	WHO guidelines on the use of chest imaging in COVID-19	<a href="https://iris.who.int/handle/10665/361833">https://iris.who.int/handle/10665/361833</a>	Clinical practice guideline
41	Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons: interim guidance, 26 October 2021	<a href="https://iris.who.int/handle/10665/347079">https://iris.who.int/handle/10665/347079</a>	Clinical practice guideline
42	Coadministration of seasonal inactivated influenza and COVID-19 vaccines: interim guidance, 21 October 2021	<a href="https://iris.who.int/handle/10665/346897">https://iris.who.int/handle/10665/346897</a>	Clinical practice guideline
43	Antigen-detection in the diagnosis of SARS-CoV-2 infection: interim guidance, 6 October 2021	<a href="https://iris.who.int/handle/10665/345948">https://iris.who.int/handle/10665/345948</a>	Clinical practice guideline
44	Corticosteroids for COVID-19: living guidance, 2 September 2020	<a href="https://iris.who.int/handle/10665/334125">https://iris.who.int/handle/10665/334125</a>	Clinical practice guideline
45	Clinical management of COVID-19: interim guidance, 27 May 2020	<a href="https://iris.who.int/handle/10665/332196">https://iris.who.int/handle/10665/332196</a>	Clinical practice guideline

46	Guidance on COVID-19 for the care of older people and people living in long-term care facilities, other non-acute care facilities and home care	<a href="https://iris.who.int/handle/10665/331913">https://iris.who.int/handle/10665/331913</a>	Clinical practice guideline
47	Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020	<a href="https://iris.who.int/handle/10665/331446">https://iris.who.int/handle/10665/331446</a>	Clinical practice guideline
48	Clinical management of adult patients with complications of pandemic influenza A (H1N1) 2009: emergency guidelines for the management of patients with severe respiratory distress and shock in district hospitals in limited-resource settings	<a href="https://iris.who.int/handle/10665/44351">https://iris.who.int/handle/10665/44351</a>	Clinical practice guideline
49	WHO rapid advice guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus	<a href="https://iris.who.int/handle/10665/69373">https://iris.who.int/handle/10665/69373</a>	Clinical practice guideline
50	Clinical management guidelines for pandemic [H1 N1] 2009 virus infection in the Eastern Mediterranean Region: technical basis and overview	<a href="https://iris.who.int/handle/10665/118127">https://iris.who.int/handle/10665/118127</a>	Clinical practice guideline
51	Guidelines for the clinical management of severe illness from influenza virus infections	<a href="https://iris.who.int/handle/10665/352453">https://iris.who.int/handle/10665/352453</a>	Clinical practice guideline
52	Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks: interim guidance for national health authorities and blood transfusion services, Version 1.0 September 2014	<a href="https://iris.who.int/handle/10665/135591">https://iris.who.int/handle/10665/135591</a>	Clinical practice guideline
53	Interim guideline: nutritional care of children and adults with Ebola virus disease in treatment centres	<a href="https://iris.who.int/handle/10665/137425">https://iris.who.int/handle/10665/137425</a>	Clinical practice guideline
54	Clinical care for survivors of Ebola virus disease: interim guidance	<a href="https://iris.who.int/handle/10665/204235">https://iris.who.int/handle/10665/204235</a>	Clinical practice guideline
55	Therapeutics for Ebola virus disease, 19 August 2022	<a href="https://iris.who.int/handle/10665/361697">https://iris.who.int/handle/10665/361697</a>	Clinical practice guideline
56	Marburg and Ebola virus infections : a guide for their diagnosis, management and control / D. I. H. Simpson	<a href="https://iris.who.int/handle/10665/37138">https://iris.who.int/handle/10665/37138</a>	Clinical practice guideline
57	Action required to address the impacts of the COVID-19 pandemic on mental health and service delivery systems in the WHO European Region: recommendations from the European Technical Advisory Group on the mental health impacts of COVID-19, 30 June 2021	<a href="https://iris.who.int/handle/10665/342932">https://iris.who.int/handle/10665/342932</a>	Health systems guidance
58	An implementation guide for the management of COVID-19 on board cargo ships and fishing vessels: interim guidance, 23	<a href="https://iris.who.int/handle/10665/350941">https://iris.who.int/handle/10665/350941</a>	Health systems guidance

59	Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers: interim guidance, 14 January 2021	<a href="https://iris.who.int/handle/10665/338689">https://iris.who.int/handle/10665/338689</a>	Health systems guidance
60	Building health systems resilience for universal health coverage and health security during the COVID-19 pandemic and beyond: WHO position paper	<a href="https://iris.who.int/handle/10665/346515">https://iris.who.int/handle/10665/346515</a>	Health systems guidance
61	Cleaning and disinfection of environmental surfaces in the context of COVID-19: interim guidance, 15 May 2020	<a href="https://iris.who.int/handle/10665/332096">https://iris.who.int/handle/10665/332096</a>	Health systems guidance
62	Communicating with patients about COVID-19 vaccination: evidence-based guidance for effective conversations to promote COVID-19 vaccine uptake	<a href="https://iris.who.int/handle/10665/340751">https://iris.who.int/handle/10665/340751</a>	Health systems guidance
63	Community-based health care, including outreach and campaigns, in the context of the COVID-19 pandemic: interim guidance, May 2020	<a href="https://iris.who.int/handle/10665/331975">https://iris.who.int/handle/10665/331975</a>	Health systems guidance
64	Conducting community engagement for COVID-19 vaccines: interim guidance, 31 January 2021	<a href="https://iris.who.int/handle/10665/339451">https://iris.who.int/handle/10665/339451</a>	Health systems guidance
65	Considerations for implementing and adjusting public health and social measures in the context of COVID-19: interim guidance, 30 March 2023	<a href="https://iris.who.int/handle/10665/366669">https://iris.who.int/handle/10665/366669</a>	Health systems guidance
66	Considerations for quarantine of contacts of COVID-19 cases: interim guidance, 25 June 2021	<a href="https://iris.who.int/handle/10665/342004">https://iris.who.int/handle/10665/342004</a>	Health systems guidance
67	Considerations in the investigation of cases and clusters of COVID-19: interim guidance, 2 April 2020	<a href="https://iris.who.int/handle/10665/331668">https://iris.who.int/handle/10665/331668</a>	Health systems guidance
68	Contact tracing and quarantine in the context of COVID-19: interim guidance, 6 July 2022	<a href="https://iris.who.int/handle/10665/358984">https://iris.who.int/handle/10665/358984</a>	Health systems guidance
69	COVID-19 immunization in refugees and migrants: principles and key considerations: interim guidance, 31 August 2021	<a href="https://iris.who.int/handle/10665/344793">https://iris.who.int/handle/10665/344793</a>	Health systems guidance
70	COVID-19 management in hotels and other entities of the accommodation sector: interim guidance, 25 August 2020	<a href="https://iris.who.int/handle/10665/333992">https://iris.who.int/handle/10665/333992</a>	Health systems guidance
71	COVID-19 vaccination in humanitarian settings: action plan from a joint convening and contributions to broader pandemic preparedness	<a href="https://iris.who.int/handle/10665/373468">https://iris.who.int/handle/10665/373468</a>	Health systems guidance
72	COVID-19 vaccination: supply and logistics guidance: interim guidance, 12 February 2021	<a href="https://iris.who.int/handle/10665/339561">https://iris.who.int/handle/10665/339561</a>	Health systems guidance
73	COVID-19: occupational health and safety for health workers: interim guidance, 2 February 2021	<a href="https://iris.who.int/handle/10665/339151">https://iris.who.int/handle/10665/339151</a>	Health systems guidance
74	Critical preparedness, readiness and response actions for COVID-19: interim guidance, 27 May 2021	<a href="https://iris.who.int/handle/10665/341520">https://iris.who.int/handle/10665/341520</a>	Health systems guidance

75	Data for action: achieving high uptake of COVID-19 vaccines: gathering and using data on the behavioural and social drivers of vaccination: a guidebook for immunization programmes and implementing partners: interim guidance, 1 April 2021	<a href="https://iris.who.int/handle/10665/340645">https://iris.who.int/handle/10665/340645</a>	Health systems guidance
76	End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: revised interim guidance, 31 January 2022	<a href="https://iris.who.int/handle/10665/351409">https://iris.who.int/handle/10665/351409</a>	Health systems guidance
77	Environmental surveillance for SARS-CoV-2 to complement other public health surveillance	<a href="https://iris.who.int/handle/10665/372995">https://iris.who.int/handle/10665/372995</a>	Health systems guidance
78	Framework for decision-making: implementation of mass vaccination campaigns in the context of COVID-19: interim guidance, 22 May 2020	<a href="https://iris.who.int/handle/10665/332159">https://iris.who.int/handle/10665/332159</a>	Health systems guidance
79	Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health, 8 January 2021	<a href="https://iris.who.int/handle/10665/338480">https://iris.who.int/handle/10665/338480</a>	Health systems guidance
80	Global analysis of healthcare waste in the context of COVID-19: status, impacts and recommendations	<a href="https://iris.who.int/handle/10665/351189">https://iris.who.int/handle/10665/351189</a>	Health systems guidance
81	Guidance for conducting a country COVID-19 after action review (AAR), 31 August 2023	<a href="https://iris.who.int/handle/10665/372578">https://iris.who.int/handle/10665/372578</a>	Health systems guidance
82	Guidance for conducting a country COVID-19 intra-action review (IAR), 23 July 2020	<a href="https://iris.who.int/handle/10665/333419">https://iris.who.int/handle/10665/333419</a>	Health systems guidance
83	Guidance for surveillance of SARS-CoV-2 variants: interim guidance, 9 August 2021	<a href="https://iris.who.int/handle/10665/343775">https://iris.who.int/handle/10665/343775</a>	Health systems guidance
84	Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines: interim guidance, 1 June 2021	<a href="https://iris.who.int/handle/10665/341564">https://iris.who.int/handle/10665/341564</a>	Health systems guidance
85	Guidance on developing national COVID-19 vaccination policy and integrating COVID-19 vaccination into national immunization programmes and broader health care delivery mechanisms in the WHO European Region: August 2023	<a href="https://iris.who.int/handle/10665/372137">https://iris.who.int/handle/10665/372137</a>	Health systems guidance
86	Guidance on operational microplanning for COVID-19 vaccination, revised 2 May 2023	<a href="https://iris.who.int/handle/10665/367267">https://iris.who.int/handle/10665/367267</a>	Health systems guidance
87	Guidance on routine immunization services during COVID-19 pandemic in the WHO European Region, 20 March 2020	<a href="https://iris.who.int/handle/10665/334123">https://iris.who.int/handle/10665/334123</a>	Health systems guidance
88	Guidance on utilization of COVID-19 vaccines before the date of expiry, 19 July	<a href="https://iris.who.int/handle/10665/343035">https://iris.who.int/handle/10665/343035</a>	Health systems guidance
89	Guiding principles for immunization activities during the COVID-19 pandemic: interim guidance, 26 March 2020	<a href="https://iris.who.int/handle/10665/331590">https://iris.who.int/handle/10665/331590</a>	Health systems guidance
90	Health financing for the COVID-19 response: process guide for national budgetary dialogue: ACT-A health systems connector	<a href="https://iris.who.int/handle/10665/343368">https://iris.who.int/handle/10665/343368</a>	Health systems guidance
91	Health for all: transforming economies to deliver what matters: final report of the WHO Council on the Economics of Health for All	<a href="https://iris.who.int/handle/10665/373122">https://iris.who.int/handle/10665/373122</a>	Health systems guidance

92	Health workforce policy and management in the context of the COVID-19 pandemic response: interim guidance, 3 December 2020	<a href="https://iris.who.int/handle/10665/337333">https://iris.who.int/handle/10665/337333</a>	Health systems guidance
93	How to use WHO risk assessment and mitigation checklist for mass gatherings in the context of COVID-19: interim guidance, 20 March 2020	<a href="https://iris.who.int/handle/10665/331536">https://iris.who.int/handle/10665/331536</a>	Health systems guidance
94	Immunization as an essential health service: guiding principles for immunization activities during the COVID-19 pandemic and other times of severe disruption, 1 November 2020	<a href="https://iris.who.int/handle/10665/336542">https://iris.who.int/handle/10665/336542</a>	Health systems guidance
95	Infection prevention and control for the safe management of a dead body in the context of COVID-19: interim guidance, 4 September	<a href="https://iris.who.int/handle/10665/334156">https://iris.who.int/handle/10665/334156</a>	Health systems guidance
96	Interim guidance for refugee and migrant health in relation to COVID-19 in the WHO European Region	<a href="https://iris.who.int/handle/10665/359103">https://iris.who.int/handle/10665/359103</a>	Health systems guidance
97	Interim recommendations for heterologous COVID-19 vaccine schedules: interim guidance, 16 December 2021	<a href="https://iris.who.int/handle/10665/350635">https://iris.who.int/handle/10665/350635</a>	Health systems guidance
98	Investing in and building longer-term health emergency preparedness during COVID-19 pandemic: interim guidance for WHO Member States	<a href="https://iris.who.int/handle/10665/332973">https://iris.who.int/handle/10665/332973</a>	Health systems guidance
99	Key planning recommendations for mass gatherings in the context of COVID-19: interim guidance, first issued 14 February 2020, third update 4 November 2021	<a href="https://iris.who.int/handle/10665/348018">https://iris.who.int/handle/10665/348018</a>	Health systems guidance
100	Laboratory biosafety guidance related to SARS-CoV-2 (COVID-19): interim guidance, updated 11 March 2024	<a href="https://iris.who.int/handle/10665/376231">https://iris.who.int/handle/10665/376231</a>	Health systems guidance
101	Maintaining a safe and adequate blood supply and collecting convalescent plasma in the context of the COVID-19 pandemic: interim guidance, 17 February 2021	<a href="https://iris.who.int/handle/10665/339793">https://iris.who.int/handle/10665/339793</a>	Health systems guidance
102	Maintaining surveillance of influenza and monitoring SARS-CoV-2: adapting Global Influenza Surveillance and Response System (GISRS) and sentinel systems during the COVID-19 pandemic: interim guidance, 8 November 2020	<a href="https://iris.who.int/handle/10665/336689">https://iris.who.int/handle/10665/336689</a>	Health systems guidance
103	Minimizing disruptions to immunization services in the context of COVID-19 in Senegal: lessons learnt and policy options	<a href="https://iris.who.int/handle/10665/372695">https://iris.who.int/handle/10665/372695</a>	Health systems guidance
104	Operational guidance: health workforce and security	<a href="https://iris.who.int/handle/10665/341117">https://iris.who.int/handle/10665/341117</a>	Health systems guidance
105	Operational guide for engaging communities in contact tracing, 28 May 2021	<a href="https://iris.who.int/handle/10665/341553">https://iris.who.int/handle/10665/341553</a>	Health systems guidance
106	Overview of public health and social measures in the context of COVID-19: interim guidance, 18 May 2020	<a href="https://iris.who.int/handle/10665/332115">https://iris.who.int/handle/10665/332115</a>	Health systems guidance

107	Oxygen sources and distribution for COVID-19 treatment centres: interim guidance, 4 April 2020	<a href="https://iris.who.int/handle/10665/331746">https://iris.who.int/handle/10665/331746</a>	Health systems guidance
108	Policy considerations for implementing a risk-based approach to international travel in the context of COVID-19, 2 July 2021	<a href="https://iris.who.int/handle/10665/342235">https://iris.who.int/handle/10665/342235</a>	Health systems guidance
109	Preparedness, prevention and control of coronavirus disease (COVID-19) for refugees and migrants in non-camp settings: interim guidance, 17 April 2020	<a href="https://iris.who.int/handle/10665/331777">https://iris.who.int/handle/10665/331777</a>	Health systems guidance
110	Promoting the health of migrant workers in the WHO European Region during COVID-19. Interim guidance, 6 November 2020	<a href="https://iris.who.int/handle/10665/336549">https://iris.who.int/handle/10665/336549</a>	Health systems guidance
111	Public health surveillance for COVID-19: interim guidance, 22 July 2022	<a href="https://iris.who.int/handle/10665/360580">https://iris.who.int/handle/10665/360580</a>	Health systems guidance
112	Reducing public health risks associated with the sale of live wild animals of mammalian species in traditional food markets: interim guidance, 12 April 2021	<a href="https://iris.who.int/handle/10665/340719">https://iris.who.int/handle/10665/340719</a>	Health systems guidance
113	Responding to community spread of COVID-19: interim guidance, 7 March 2020	<a href="https://iris.who.int/handle/10665/331421">https://iris.who.int/handle/10665/331421</a>	Health systems guidance
114	Risk communication and community engagement for COVID-19 contact tracing: interim guidance	<a href="https://iris.who.int/handle/10665/339100">https://iris.who.int/handle/10665/339100</a>	Health systems guidance
115	SARS-CoV-2 genomic sequencing for public health goals: interim guidance, 8 January 2021	<a href="https://iris.who.int/handle/10665/338483">https://iris.who.int/handle/10665/338483</a>	Health systems guidance
116	Schooling during COVID-19: recommendations from the European Technical Advisory Group for schooling during COVID-19, June 2021	<a href="https://iris.who.int/handle/10665/342075">https://iris.who.int/handle/10665/342075</a>	Health systems guidance
117	Schooling in the time of COVID-19: towards a consensus on schooling in the European Region during the COVID-19 pandemic	<a href="https://iris.who.int/handle/10665/350202">https://iris.who.int/handle/10665/350202</a>	Health systems guidance
118	Strategic preparedness, readiness and response plan to end the global COVID-19 emergency in 2022	<a href="https://iris.who.int/handle/10665/352861">https://iris.who.int/handle/10665/352861</a>	Health systems guidance
119	Strategies to facilitate sharing of technology and knowledge through WHO COVID-19 Technology Access Pool	<a href="https://iris.who.int/handle/10665/373133">https://iris.who.int/handle/10665/373133</a>	Health systems guidance
120	Strengthening and adjusting public health measures throughout the COVID-19 transition phases: policy considerations for the WHO European Region, 24 April 2020	<a href="https://iris.who.int/handle/10665/332467">https://iris.who.int/handle/10665/332467</a>	Health systems guidance
121	Strengthening COVID-19 vaccine demand and uptake in refugees and migrants: an operational guide to support all those responsible for planning and implementing the rollout of COVID-19 vaccine to refugees and migrants at national and local levels, 14 March 2022	<a href="https://iris.who.int/handle/10665/352415">https://iris.who.int/handle/10665/352415</a>	Health systems guidance
122	Strengthening preparedness for COVID-19 in cities and urban settings: interim guidance for local authorities	<a href="https://iris.who.int/handle/10665/331896">https://iris.who.int/handle/10665/331896</a>	Health systems guidance

123	Strengthening the health system response to COVID-19: technical guidance #1: maintaining the delivery of essential health care services while mobilizing the health workforce for the COVID-19 response, 18	<a href="https://iris.who.int/handle/10665/332559">https://iris.who.int/handle/10665/332559</a>	Health systems guidance
124	Surveillance strategies for COVID-19 human infection: interim guidance, 10 May 2020	<a href="https://iris.who.int/handle/10665/332051">https://iris.who.int/handle/10665/332051</a>	Health systems guidance
125	The future of WHO Covid-19 response operations in Africa in 2022	<a href="https://iris.who.int/handle/10665/359157">https://iris.who.int/handle/10665/359157</a>	Health systems guidance
126	The role of community health workers in COVID-19 vaccination: implementation support guide, 26 April 2021	<a href="https://iris.who.int/handle/10665/340986">https://iris.who.int/handle/10665/340986</a>	Health systems guidance
127	Water, sanitation, hygiene, and waste management for SARS-CoV-2, the virus that causes COVID-19: interim guidance, 29 July 2020	<a href="https://iris.who.int/handle/10665/333560">https://iris.who.int/handle/10665/333560</a>	Health systems guidance
128	Western Pacific Regional guide for the immunization programme and vaccine-preventable disease surveillance during the COVID-19 pandemic	<a href="https://iris.who.int/handle/10665/336861">https://iris.who.int/handle/10665/336861</a>	Health systems guidance
129	WHO guidance on research methods for health emergency and disaster risk management	<a href="https://iris.who.int/handle/10665/363502">https://iris.who.int/handle/10665/363502</a>	Health systems guidance
130	WHO interim guidance note: health workforce response to the COVID-19 pandemic: April 2020	<a href="https://iris.who.int/handle/10665/331949">https://iris.who.int/handle/10665/331949</a>	Health systems guidance
131	WHO Western Pacific regional action plan for the response to large-scale community outbreaks of COVID-19	<a href="https://iris.who.int/handle/10665/331944">https://iris.who.int/handle/10665/331944</a>	Health systems guidance
132	WHO recommended measures for persons undertaking international travel from areas affected by Severe Acute Respiratory Syndrome (SARS) = Mesures recommandées par l'OMS à l'intention des voyageurs provenant de zones touchées par le syndrome respiratoire aigu sévère (SRAS)	<a href="https://iris.who.int/handle/10665/232135">https://iris.who.int/handle/10665/232135</a>	Health systems guidance
133	Syndrome respiratoire aigu sévère (SRAS)	<a href="https://iris.who.int/handle/10665/248792">https://iris.who.int/handle/10665/248792</a>	Health systems guidance
134	Riposte aux flambées: syndrome respiratoire aigu sévère (SRAS) et grippe, et rapport d'activité sur la révision du règlement sanitaire international	<a href="https://iris.who.int/handle/10665/248828">https://iris.who.int/handle/10665/248828</a>	Health systems guidance
135	Riposte aux flambées: syndrome respiratoire aigu sévère (SRAS) et grippe, et révision du règlement sanitaire international (résolution)	<a href="https://iris.who.int/handle/10665/248856">https://iris.who.int/handle/10665/248856</a>	Health systems guidance
136	Síndrome respiratorio agudo severo (SRAS)	<a href="https://iris.who.int/handle/10665/80223">https://iris.who.int/handle/10665/80223</a>	Health systems guidance
137	Révision du Règlement sanitaire international: Syndrome respiratoire aigu sévère (SRAS): Rapport du Secrétariat	<a href="https://iris.who.int/handle/10665/85098">https://iris.who.int/handle/10665/85098</a>	Health systems guidance
138	Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccines and other benefits	<a href="https://iris.who.int/handle/10665/44796">https://iris.who.int/handle/10665/44796</a>	Health systems guidance

139	WHO guidance on development of influenza vaccine reference viruses by reverse genetics	<a href="https://iris.who.int/handle/10665/69051">https://iris.who.int/handle/10665/69051</a>	Health systems guidance
140	Responding to the avian influenza pandemic threat: recommended strategic actions	<a href="https://iris.who.int/handle/10665/69103">https://iris.who.int/handle/10665/69103</a>	Health systems guidance
141	Collecting, preserving and shipping specimens for the diagnosis of avian influenza A(H5N1) virus infection: guide for field operations	<a href="https://iris.who.int/handle/10665/69392">https://iris.who.int/handle/10665/69392</a>	Health systems guidance
142	WHO strategic action plan for pandemic influenza	<a href="https://iris.who.int/handle/10665/70038">https://iris.who.int/handle/10665/70038</a>	Health systems guidance
143	Recommendations for good practice in pandemic preparedness for National Influenza Centres: evaluation of how pandemic preparedness activities aided National Influenza Centres in the WHO European Region in the response to pandemic (H1N1) 2009	<a href="https://iris.who.int/handle/10665/108594">https://iris.who.int/handle/10665/108594</a>	Health systems guidance
144	Operational guidance on sharing influenza viruses with human pandemic potential (IVPP) under the Pandemic influenza preparedness (PIP) framework	<a href="https://iris.who.int/handle/10665/259402">https://iris.who.int/handle/10665/259402</a>	Health systems guidance
145	A guide to develop the methodology, tools and the summary report of the joint national and international review of influenza sentinel surveillance in WHO 's South-East Asia Region	<a href="https://iris.who.int/handle/10665/371398">https://iris.who.int/handle/10665/371398</a>	Health systems guidance
146	Guidance on development and implementation of a national deployment and vaccination plan for vaccines against pandemic influenza and other respiratory viruses of pandemic potential	<a href="https://iris.who.int/handle/10665/374995">https://iris.who.int/handle/10665/374995</a>	Health systems guidance
147	Considerations for mass gathering events and Middle East respiratory syndrome coronavirus (MERS-CoV): interim guidance: updated May 2018	<a href="https://iris.who.int/handle/10665/272521">https://iris.who.int/handle/10665/272521</a>	Health systems guidance
148	Surveillance for human infection with Middle East respiratory syndrome coronavirus (MERS-CoV): interim guidance	<a href="https://iris.who.int/handle/10665/177869">https://iris.who.int/handle/10665/177869</a>	Health systems guidance
149	Ebola response roadmap	<a href="https://iris.who.int/handle/10665/131596">https://iris.who.int/handle/10665/131596</a>	Health systems guidance
150	WHO information note: guidance for immunization programmes in the African Region in the context of Ebola	<a href="https://iris.who.int/handle/10665/137330">https://iris.who.int/handle/10665/137330</a>	Health systems guidance
151	Infectious Disease Contact Tracing	<a href="https://iris.who.int/handle/10665/159040">https://iris.who.int/handle/10665/159040</a>	Health systems guidance
152	2015 WHO strategic response plan: West Africa Ebola outbreak	<a href="https://iris.who.int/handle/10665/163360">https://iris.who.int/handle/10665/163360</a>	Health systems guidance
153	Technical meeting to support Ebola-affected countries on the recovery and resilience plans with a focus on GAVI, the Global Fund and other partners' funding, 9-11 June 2015, Accra, Ghana	<a href="https://iris.who.int/handle/10665/180816">https://iris.who.int/handle/10665/180816</a>	Health systems guidance

- 154 Implementation and management of contact tracing for Ebola virus disease: emergency guideline <https://iris.who.int/handle/10665/185258> Health systems guidance
- 155 Emergency guidance: surveillance strategy during Phase 3 of the Ebola response <https://iris.who.int/handle/10665/192997> Health systems guidance
- 156 Infection prevention and control recovery plans and implementation: Guinea, Liberia, and Sierra Leone inter-country meeting: final report, 20-22 July 2015, Monrovia, Liberia <https://iris.who.int/handle/10665/204370> Health systems guidance
- 157 Sixty-sixth Regional Committee for Europe: Copenhagen, 12 – 15 September 2016: draft global implementation plan for the recommendations of the Review Committee on the Role of the International Health Regulations (2005) in the Ebola Outbreak and Response <https://iris.who.int/handle/10665/338211> Health systems guidance
-

**Table S4.** Comparison for evaluation content of the AGREE II versus AGREE-HS.

	AGREE II	AGREE-HS
	Domain NO./Item NO./Item element	Item NO./Criterion NO./Criterion element
<b>Common</b>	1.3.target population 2.4.all relevant groups 2.5.target population views 3.7.systematic methods 3.8.criteria for selecting evidence 3.10.methods for formulation 3.11.benefits and risks 3.12.explicit link 3.14.a procedure for updating 4.15.specific and unambiguous 5.18.facilitators and barriers 5.20.potential resource 5.21.monitor and/or audit 6.22.views of the funding body 6.23.competing interests OA.2.recommend for use	1.1.the populations affected 2.5.stakeholders 2.5.members of the public 3.10.systematic and transparent methods 3.11.best and most relevant evidence 3.18.systematic and transparent methods 3.15.benefits and harms weighting 3.16.link 4.26.a plan for updating 4.25.detailed to be operationalized 5.27.barriers and enablers 5.28.cost and resource 5.35.strategies for assessing the implementation 2.9.influence of a funding agency 2.8.competing interests OA.1.recommend for use in appropriate context
<b>Unique</b>	1.1.overall objective(s) 1.2.health question(s)  2.6.target users  3.9.strengths and limitations of evidence 3.13.external review  4.16.different options 4.17.key recommendations  5.19.apply advice and/or tools	1.1.health system challenge attributes 1.2.health system challenge causes 1.3.health system challenge level of priority 1.4.relevance of the topic 2.6.multidisciplinary development team 2.7.multi-sectoral development team 3.12.current evidence base 3.13.effectiveness of potential options 3.14.cost and cost-effectiveness of potential options 3.17.rationale behind the recommendations 4.19.anticipated outcomes 4.20.comprehensiveness 4.21.ethical principles 4.22.equity promotion 4.23.socio-cultural and political alignment 4.24.clear and succinct recommendations 5.29.stakeholders' acceptability 5.30.affordability 5.31.sustainability and requirements 5.32.flexibility 5.33.transferability  5.34.strategies for dissemination
	OA.1.overall quality rating	OA.2.recommend for use in assessor's context
AGREE II – Appraisal of Guidelines for Research & Evaluation II, AGREE-HS – Appraisal of Guidelines for Research and Evaluation - Health Systems, OA – Overall assessment.		

**Table S5.** Comparison for evaluation content of the AGREE II versus AGREE-HS (original content from the manuals).

AGREE II		AGREE-HS	
Domain 1. Scope and purpose	<p>1.The overall objective(s) of the guideline is (are) specifically described.</p> <p>2.The health question(s) covered by the guideline is (are) specifically described.</p> <p>3.The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described.</p>	Item 1: Topic	<p>1.The health system challenge is clearly described (i.e., the nature of the challenge; the magnitude, frequency or intensity of the challenge; the populations affected).</p> <p>2.The causes of the health system challenge are clearly described.</p> <p>3.The health system challenge is described in terms of its level of priority in the targeted health system and the affected population; arguments to support the priority classification are provided.</p> <p>4.The guidance is relevant to (i.e., timely in relation to when decisions will be made), and appropriate for, the health system challenge, the system or sub-system needs, the target population(s), and the setting(s) in which they will operate.</p>
Domain 2. Stakeholder involvement	<p>4.The guideline development group includes individuals from all relevant professional groups.</p> <p>5.The views and preferences of the target population (patients, public, etc.) have been sought.</p> <p>6.The target users of the guideline are clearly defined.</p>	Item 2: Participants	<p>5.The health systems guidance development team includes members who have an interest or stake in the recommendations (e.g., decision makers, program managers, operational leaders, consumers and members of the public).</p> <p>6.The health systems guidance development team is multidisciplinary (e.g., political scientists, economists, epidemiologists, methodologists).</p> <p>7.The health systems guidance development team is multi-sectoral (e.g., primary care, public health and, if appropriate to the challenge, finance and housing).</p> <p>8.Competing interests of the health systems guidance development team members (e.g., financial, professional), and the strategies used to identify and manage them, are</p> <p>9.Precautions have been taken to avoid or to minimize the influence of a funding agency.</p>

Domain 3. Rigour of development	<p>7.Systematic methods were used to search for evidence.</p> <p>8.The criteria for selecting the evidence are clearly described.</p> <p>9.The strengths and limitations of the body of evidence are clearly described.</p> <p>10.The methods for formulating the recommendations are clearly described.</p> <p>11.The health benefits, side effects, and risks have been considered in formulating the recommendations.</p> <p>12.There is an explicit link between the recommendations and the supporting evidence.</p> <p>13.The guideline has been externally reviewed by experts prior to its publication.</p> <p>14.A procedure for updating the guideline is provided.</p>	Item 3: Methods	<p>10.Systematic and transparent methods were used to identify and review the evidence (e.g., integrated review, scoping review, review of the grey literature, systematic review).</p> <p>11.The best available and most contextually relevant evidence was considered.</p> <p>12.The evidence base is current.</p> <p>13.Evidence of effectiveness of the potential options is clearly described, including descriptions of the contexts in which the options were tested.</p> <p>14.Evidence of cost and cost-effectiveness of the potential options is described.</p> <p>15.The weighting of the benefits and harms of the potential options is described.</p> <p>16.There is a link between the recommendations and evidence.</p> <p>17.The rationale behind the recommendations is clear.</p> <p>18.Systematic and transparent methods were used to agree upon the final recommendations (e.g., informal or formal consensus, Delphi method, nominal group methods).</p>
Domain 4. Clarity of presentation	<p>15.The recommendations are specific and unambiguous.</p> <p>16.The different options for management of the condition or health issue are clearly presented.</p> <p>17.Key recommendations are easily identifiable.</p>	Item 4: Recommendations	<p>19.The anticipated outcomes of implementing the recommendations are clearly described (including indicators, performance thresholds or targets, and standards to measure them).</p> <p>20.The recommendations are comprehensive and provide direction to all relevant health system levels (e.g., national, provincial/state), subsystems (e.g., cancer, mental health) and sectors (e.g., primary care, public health).</p> <p>21.The ethical principles used to develop the recommendations are described.</p> <p>22.The recommendations promote equity among the target population (e.g., in terms of age, sex, gender, culture, religion, race, sexual orientation).</p>

		<p>23.The recommendations , acceptability to, and alignment with sociocultural and political interests were considered.</p> <p>24.The recommendations are easily identifiable, clear, and succinct.</p> <p>25.The recommendations are actionable and are sufficiently detailed to be operationalized.</p> <p>26.A plan for updating the recommendations is described.</p>
Domain 5. Applicability	<p>18.The guideline describes facilitators and barriers to its application.</p> <p>19.The guideline provides advice and/or tools on how the recommendations can be put into practice.</p> <p>20.The potential resource implications of applying the recommendations have been considered.</p> <p>21.The guideline presents monitoring and/or auditing criteria.</p>	<p>Item 5: Implementability</p> <p>27.Barriers and enablers to the implementation of the recommendations are described, including factors that are internal (e.g., resources, incentives, administrative structure) and external (e.g., legal system, social system, state of the economy, corruption, beliefs) to the health system. A plan to mitigate barriers and optimize enablers is included.</p> <p>28.Cost and resource considerations for the recommended actions are described (e.g., money, time, infrastructure, equipment, administrative capacity, supplies, staffing, and training).</p> <p>29.The stakeholders' acceptability of the recommendations is described.</p> <p>30.The affordability of the recommendations, in the context where implementation will take place, is described.</p> <p>31.The anticipated sustainability and requirements to maintain long-term outcomes is described.</p> <p>32.The recommendations are flexible and there is a description of how they can be adapted or tailored for specific contexts in which they will be implemented.</p> <p>33.A description of the degree to which the recommendations are transferable to other similar or different contexts is provided.</p> <p>34.Strategies for disseminating the health systems guidance are described.</p>

		35.Strategies for assessing the implementation process and the impact of the recommendations are described.													
Domain 6. Editorial independence	22.The views of the funding body have not influenced the content of the guideline.  23.Competing interests of guideline development group members have been recorded and addressed.	-													
Overall guideline assessment	Overall Assessment  1. Rate the overall quality of this guideline. <table border="1"><tr><td>1 Lowest possible quality</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7 Highest possible quality</td></tr></table> 2. I would recommend this guideline for use. <table border="1"><tr><td>Yes</td><td></td></tr><tr><td>Yes, with modifications</td><td></td></tr><tr><td>No</td><td></td></tr></table>	1 Lowest possible quality	2	3	4	5	6	7 Highest possible quality	Yes		Yes, with modifications		No		1.I would recommend this health systems guidance for use <b>in the appropriate context.</b> Yes Yes, with modifications No  2.I would recommend this health systems guidance for use <b>in my context</b> (optional). Yes Yes, with modifications No
1 Lowest possible quality	2	3	4	5	6	7 Highest possible quality									
Yes															
Yes, with modifications															
No															

**Table S6.** Comparison for different scoring methods.

	Clinical practice guidelines			Integrated guidelines			
	Manual	New	<i>P</i> -value	Manual	New	<i>P</i> -value	
AGREE II	Domain 1	85.3%±12.5%	6.12±0.75	/	76.0%±10.0%	5.56±0.60	/
	Domain 2	66.0%±15.7%	4.96±0.94	/	53.3%±14.5%	4.20±0.87	/
	Domain 3	68.1%±18.6%	5.08±1.11	/	48.7%±22.1%	3.92±1.32	/
	Domain 4	84.0%±10.8%	6.04±0.65	/	73.5%±12.3%	5.41±0.74	/
	Domain 5	54.9%±14.9%	4.29±0.90	/	51.3%±15.0%	4.08±0.90	/
	Domain 6	70.0%±24.1%	5.20±1.45	/	31.7%±28.5%	2.90±1.71	/
	Overall	5.50±0.71	5.45±0.83	0.309	4.49±0.90	4.35±0.77	0.478
AGREE-HS	Health systems guidance			Integrated guidelines			
	Manual	New	<i>P</i> -value	Manual	New	<i>P</i> -value	
	Item 1	5.26±0.77	4.91±0.72	0.366	5.26±0.77	4.99±0.75	0.145
	Item 2	4.07±1.38	3.94±1.18	0.384	4.07±1.38	3.76±1.30	0.334
	Item 3	4.51±1.16	4.26±0.90	0.418	4.51±1.16	4.31±1.05	0.451
	Item 4	5.28±0.66	5.13±0.70	0.397	5.28±0.66	5.02±0.67	0.120
	Item 5	3.75±0.87	3.81±0.82	0.222	3.75±0.87	3.77±0.83	0.901
	Overall	56.5%±11.4	4.19±0.69	/	59.6%±12.4	4.37±0.71	/

**Table S7.** The scores of the AGREE II and AGREE-HS over the 36 integrated guidelines.

	Domains/Items	Raw Score <sup>a</sup>	Transformed Score <sup>b</sup>
		Mean $\pm$ SD	Mean $\pm$ SD
<b>AGREE II</b>	Scope and purpose	5.56 $\pm$ 0.60	76.0% $\pm$ 10.0%
	Stakeholder involvement	4.20 $\pm$ 0.87	53.3% $\pm$ 14.5%
	Rigour of development	3.92 $\pm$ 1.32	48.7% $\pm$ 22.1%
	Clarity of presentation	5.41 $\pm$ 0.74	73.5% $\pm$ 12.3%
	Applicability	4.08 $\pm$ 0.90	51.3% $\pm$ 15.0%
	Editorial independence	2.90 $\pm$ 1.71	31.7% $\pm$ 28.5%
	Overall Score <sup>c</sup>	4.35 $\pm$ 0.77	55.8% $\pm$ 12.8%
<b>AGREE-HS</b>	Topic	4.99 $\pm$ 0.75	66.5% $\pm$ 12.5%
	Participants	3.76 $\pm$ 1.30	46.0% $\pm$ 21.7%
	Methods	4.31 $\pm$ 1.05	55.2% $\pm$ 17.5%
	Recommendations	5.02 $\pm$ 0.67	67.1% $\pm$ 11.2%
	Implementability	3.77 $\pm$ 0.83	46.2% $\pm$ 13.9%
	Overall Score <sup>c</sup>	4.37 $\pm$ 0.71	56.2% $\pm$ 11.9%

SD – standard deviation.

<sup>a</sup> Mean score of the domain or item over all guidelines.

<sup>b</sup> Calculated score according to the formula:  $\frac{\text{Obtained score} - \text{Minimum possible score}}{\text{Maximum possible score} - \text{Minimum possible score}}$

<sup>c</sup> Newly calculated mean score of six domains for AGREE II or five items for AGREE-HS.

**Table S8.** Assessors' will to recommend the guidelines for use.

<b>Assessor recommendations</b>	<b>Clinical guidelines</b>	<b>Health system guidelines</b>	<b>Integrated guidelines</b>
Both "Yes"	8 (40.0%)	1 (0.9%)	4 (11.1%)
Both "Yes, with modifications"	5 (25.0%)	71 (70.3%)	11 (30.6%)
Both "No"	0	7 (6.9%)	1 (2.8%)
"Yes"/"Yes, with modifications"	7 (35.0%)	6 (5.9%)	15 (41.7%)
"No"/"Yes, with modifications"	0	16 (15.8%)	5 (13.9%)
"Yes"/"No"	0	0	0

**Table S9.** Comparison for overall scores of included guidelines.

	Overall Score		<i>P</i> -value
	AGREE II	AGREE-HS	
<b>Clinical guidelines</b>	5.28 ± 0.81	-	0.000 <sup>a</sup>
<b>Health system guidelines</b>	-	4.19 ± 0.69	0.185 <sup>b</sup>
<b>Integrated guidelines</b>	4.35 ± 0.77	4.37 ± 0.71	0.889 <sup>c</sup>

<sup>a</sup> The *P*-value indicates difference between overall scores of integrated guidelines and overall scores of clinical guidelines when evaluated by the AGREE II.

<sup>b</sup> The *P*-value indicates difference between overall scores of integrated guidelines and overall scores of health system guidelines when evaluated by the AGREE-HS.

<sup>c</sup> The *P*-value indicates difference between overall scores of integrated guidelines when evaluated separately by the AGREE II and AGREE-HS.